Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476717 | 0.82 | MEN1 (0.67) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL17488471 | 0.80 | MEN1 (0.63) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL29224597 | 0.79 | ERCC1 (0.74) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL29224595 | 0.79 | ERCC1 (0.74) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL29224596 | 0.79 | ERCC1 (0.74) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL15543489 | 0.77 | — | — | |
| SCHEMBL5197621 | 0.76 | CYP1A2 (0.59) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL7103339 | 0.75 | MEN1 (0.57) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL7103335 | 0.75 | MEN1 (0.57) | MEN1KMT2ACYP3A4TSHRCYP1A2 | |
| SCHEMBL17667848 | 0.75 | CYP3A4 (0.60) | MEN1KMT2ACYP3A4TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | LEHIGH UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-9512068-B2 | Augmenting moieties for anti-inflammatory compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | PTGES, PTGES3, LRBA | MEN1 4522/4885KMT2A 2466/4885CYP3A4 403/4885 |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, ICAM1, VCAM1 | MEN1 4476/4885KMT2A 2489/4885CYP3A4 1131/4885 |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, PTGES3, LRBA | MEN1 4522/4885KMT2A 2466/4885CYP3A4 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.